Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

White Button Mushroom Sup for reduksjon av PSA i Pts med biokjemisk behandling eller terapi Naiv Fav Risiko Prostata CA

2. november 2026 oppdatert av: City of Hope Medical Center

En randomisert fase 2-forsøk med tilskudd av hvitknappssopp hos pasienter med biokjemisk tilbakevendende prostatakreft etter lokal terapi og i terapi Tidligere pasienter med gunstig risiko for prostatakreft som gjennomgår aktiv overvåking

This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not undergone any therapy (therapy naive). PSA is a blood marker of prostate growth. White button mushroom supplement may affect PSA level, various parameters of immune system and levels of hormones that may have a role in prostate cancer growth.

Studieoversikt

Status

Suspendert

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. To assess the proportion of patients with any prostate specific antigen (PSA) reduction at 12 weeks (~3 months) in observation + white button mushroom (WBM) supplement arm and observation only arm (control arm). (Cohort 1) II. To assess relative change in PSA at 48 weeks (~12 months) from baseline with or without WBM treatment. (Cohort 2)

SECONDARY OBJECTIVES:

I. To evaluate, adverse events, PSA-response rate and time to PSA progression. (Cohort 1) II. To evaluate adverse events, time to initiation of additional therapy and progression. (Cohort 2)

EXPLORATORY OBJECTIVES:

I. To characterize the immunomodulatory effects of WBM supplement in serial blood samples. (Cohort 1) II. To assess the effect of therapy with WBM on sexual function. (Cohort 1) III. To assess the effect of WBM on Gleason grade in prostate cancer subjects on active surveillance. (Cohort 2) IV. To characterize the immunomodulatory effects of WBM supplement in serial blood samples and in tumor tissue. (Cohort 2) V. To characterize changes in cancer signaling pathways in tumor tissue after intake of WBM supplement. (Cohort 2) VI. To assess the effect of WBM supplement on sexual function. (Cohort 2)

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT I: Biochemically recurrent prostate cancer patients are randomized to 1 of 2 arms.

ARM IA: Patients receive white button mushroom extract orally (PO) twice daily (BID) on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.

ARM IB: Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.

COHORT II: Therapy naive favorable risk prostate cancer patients are randomized to 1 of 2 arms.

ARM IIA: Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.

ARM IIB: Patients undergo active surveillance for 48 weeks.

After completion of study treatment, patients are followed up at 30 days.

Studietype

Intervensjonell

Registrering (Faktiske)

133

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • City of Hope Medical Center
      • Glendora, California, Forente stater, 91741
        • City of Hope at Glendora
      • Irvine, California, Forente stater, 92618
        • City of Hope at Irvine Lennar
      • Rancho Cucamonga, California, Forente stater, 91730
        • City of Hope Rancho Cucamonga
      • Santa Monica, California, Forente stater, 90404
        • John Wayne Cancer Institute
      • South Pasadena, California, Forente stater, 91030
        • City of Hope South Pasadena
      • West Covina, California, Forente stater, 91790
        • City of Hope West Covina

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

  • For therapy naive favorable risk prostate cancer (cohort 2 only): agreement to undergo baseline and 48 week prostate biopsy

  • Willing to forego non-study supplements containing mushroom for the duration of the study

  • Eastern Cooperative Oncology Group (ECOG) =< 2

  • Histologically or cytologically confirmed history of adenocarcinoma of the prostate

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: PSA failure defined as:

    • PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy, OR
    • PSA increase of 2.0 ng/mL above post-therapy nadir if other primary local therapy was used instead of prostatectomy
    • NOTE: PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart
  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Testosterone levels > 50 ng/dL

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Received any number of primary local therapies, defined as:

    • Radical prostatectomy
    • External beam radiation therapy
    • Radioactive seed implantation
    • Cryotherapy
    • High-intensity focused ultrasound (HIFU)
  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy. Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy. If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan

  • THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adenocarcinoma of the prostate diagnosed =< 12 months of protocol screening and has elected active surveillance as preferred management plan OR already on active surveillance

  • THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Clinical stage T1c-T2a as defined below:

    • T1c: Tumor identified by needle biopsy found in one or both sides, but not palpable
    • T2a: Tumor involves one-half of one side or less
  • THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)

  • THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adequate biopsy of at least 10 biopsy cores

  • THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: No prior therapy for prostate cancer defined as:

    • Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)
    • Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy). Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed
  • Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)

  • Hemoglobin > 8 g/dL (within 28 days prior to day 1 of protocol therapy)

  • Aspartate aminotransferase, alanine aminotransferase, < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)

  • Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)

  • Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)

Exclusion Criteria:

  • Other concomitant investigational anti-cancer therapy/ vaccines/biologics, corticosteroids with > 10 mg of prednisone equivalent dose

  • Therapy with mushroom supplements within last 3 months of randomization

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months or within 6 months prior to day 1 of protocol therapy

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy

  • BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy):

    • Chemotherapy
    • Androgen deprivation therapy
    • Immunotherapy
    • Targeted therapy
  • Known history of allergic reaction to mushrooms

  • Clinically significant uncontrolled illness

  • Active infection requiring treatment

  • Uncontrolled congestive heart failure, cardiac arrhythmia

  • History of other primary non-skin malignancy within previous 2 years unless treated with curative intent and in remission

  • Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures

  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm IA (white mushroom extract)

Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Given PO

Andre navn:
  • WBM-ekstrakt
Aktiv komparator: Arm IB (clinical observation)

Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.

Ancillary studies

Undergo clinical observation

Andre navn:
  • observasjon
Eksperimentell: Arm IIA (white mushroom extract)

Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Given PO

Andre navn:
  • WBM-ekstrakt
Aktiv komparator: Arm IIB (active surveillance)

Patients undergo active surveillance for 48 weeks.

Ancillary studies

Undergo active surveillance

Andre navn:
  • observasjon
  • Aktiv overvåking
  • utsatt terapi
  • forventningsfull ledelse
  • Vaken venter

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prostate-specific antigen (PSA) (ng/mL) levels (Cohort 1)
Tidsramme: At 12 weeks

For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

At 12 weeks
Relative change in PSA (Cohort 2)
Tidsramme: Baseline up to 48 weeks

The relative difference in PSA will be measured as log (48 week PSA/baseline PSA). Undetectable PSA at 48 weeks will be coded as the low end of the lab measurement range for PSA. This measure of relative difference will be compared between the white button supplement (WBM) + active surveillance and active surveillance only patients. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

Baseline up to 48 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events
Tidsramme: Up to 48 weeks

Will be defined per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Grade 2 serious adverse events and all grade 3-5 adverse events will be reported in the e-case report forms. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, attribution, time of onset, probable association with the study treatment and reversibility or outcome.

Up to 48 weeks
Proportion of patients with PSA response (Cohort 1)
Tidsramme: Up to 48 weeks

Will be defined as the sum of complete (PSA-normalization) and partial responders (PSA-partial response) vs non-responders. For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

Up to 48 weeks
Time to PSA progression (Cohort 1)
Tidsramme: Time from randomization to PSA progression, assessed up to 48 weeks

For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

Time from randomization to PSA progression, assessed up to 48 weeks
Time to initiation of additional therapy (Cohort 2)
Tidsramme: Baseline up to 48 weeks

For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

Baseline up to 48 weeks
Time to progression (Cohort 2)
Tidsramme: From randomization to progression, assessed up to 48 weeks

Will be defined as any Gleason grade 4 or 5 upon repeat biopsy or conversion from 3+4 to 4+3 or higher, prostate cancer is found in a greater number of prostate biopsy cores, prostate cancer occupies a greater extent of the prostate biopsy cores, PSA > 100 ng/mL. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided.

From randomization to progression, assessed up to 48 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in temporal levels of circulating myeloid-derived suppressor cells (MDSCs)
Tidsramme: Baseline to 48 weeks

Will be studies within the peripheral blood mononuclear cell (PBMC) compartment. Will evaluate the relative change in prostate cancer-associated MDSCs after 12 weeks of WBM supplement intake in borderline resectable pancreatic cancer patients versus in those on observation using a two group t-test. Results for cohort 1 will be confirmed by analyzing prostate cancer-associated MDSCs in cohort 2 as well (change from baseline to 48 weeks).

Baseline to 48 weeks
Change in temporal levels of pro-/anti-inflammatory mediators
Tidsramme: Baseline up to 48 weeks

Will include cytokines/growth factors/chemokines, including IL-15 in plasma. Will evaluate the baseline correlatives and the relative role of treatment in a multivariate exploratory analysis.

Baseline up to 48 weeks
Sexual function
Tidsramme: Up to 48 weeks

Will be evaluated by the sexual function questionnaire, including the Sexual Health Inventory for Men score. The Sexual Health Inventory for Men (SHIM) Questionnaire scoring system will be used.

Up to 48 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Clayton S Lau, City of Hope Medical Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. mai 2021

Primær fullføring (Faktiske)

31. mars 2026

Studiet fullført (Antatt)

14. mai 2027

Datoer for studieregistrering

Først innsendt

12. september 2019

Først innsendt som oppfylte QC-kriteriene

17. august 2020

Først lagt ut (Faktiske)

20. august 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 19296
  • P30CA033572 (U.S. NIH-stipend/kontrakt)
  • 19296 (Annen identifikator: City of Hope Medical Center)
  • NCI-2019-05587 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .